Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients

NCT02384967 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

OTHER_GOV

Sponsor class

Conditions

HIV INFECTION

Interventions

DRUG: Darunavir

Sponsor

ANRS, Emerging Infectious Diseases